GT
SYRS

Glenmede Trust’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Glenmede Trust’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-932
Closed -$148K – 2861
2017
Q2 		$148K Hold
932
– – ﹤0.01% 1287
2017
Q1 		$148K Hold
932
– – ﹤0.01% 1287
2016
Q4 		$113K Hold
932
– – ﹤0.01% 1371
2016
Q3 		$129K Buy
+932
New +$118K ﹤0.01% 1324

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's SYRS Position: Q3 2017 in Review

Glenmede Trust sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2017, closing a stake of 932 shares — an estimated $148K sold.

Glenmede Trust first reported a position in SYRS in Q3 2016 and held it in 4 quarters. The position peaked at $148K in Q2 2017. 68 funds tracked by Wall St. Rank hold SYRS as of Q3 2017.

  • Glenmede Trust reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Glenmede Trust sold 932 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2017, an estimated $148K.
  • Glenmede Trust first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 4 quarters.
  • Glenmede Trust's Syros Pharmaceuticals, Inc. Common Stock position peaked at $148K in Q2 2017.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2017.

Based on Glenmede Trust's 13F filing for Q3 2017, filed 14 Nov 2017.